Press Releases
Madrid, Spain — November 14, 2025
Veos Pharmaceuticals Expands North American Presence with Acquisition of SSD Trading Canada’s Amazon Wellness Portfolio.
Madrid, Spain — November 14, 2025 — Veos Pharmaceuticals S.L. (“Veos” or the “Company”), a Madrid-based specialty healthcare and consumer wellness company, announced today that it has signed a definitive agreement to acquire, in an all-cash transaction, the Canadian Amazon operations and wellness brand portfolio of SSD Trading Canada 18 Ltd. The acquisition includes three established Amazon.ca brands: Copper Heal™, Petting is Caring™, and F1TNERGY™.
The transaction is expected to close within the next four weeks, subject to customary closing conditions.
The acquired brands collectively generated nearly CAD $0.5 million in verified net sales during the last fiscal year and benefit from thousands of 4- and 5-star reviews from Canadian consumers. They occupy strong positions in their Amazon categories and have proven long-term demand.
“These Canadian brands have earned deep trust from consumers, and they fit perfectly within our strategy of building a global portfolio of high-quality, data-driven wellness products,” said Dr. Bassam Damaj, President and CEO of Veos Pharmaceuticals. “Our Amazon infrastructure and digital marketing capabilities will strengthen their reach and accelerate their growth.”
Veos will maintain the brands’ Canadian market identity, while enhancing product availability, marketing performance, inventory planning, and operational efficiency through centralized logistics and digital-commerce systems.
“These are exactly the type of high-performing assets we look for: established, profitable, and trusted by consumers,” said Samira Wifak, Managing Partner at Veos Ventures. “By integrating SSD’s portfolio into our broader consumer-health platform, we will preserve each brand’s market strength and unlock additional scale through our data-driven supply chain and marketing infrastructure.”
Projected first-year ROI is above 50%, driven by marketing efficiencies, improved logistics, and operational consolidation between Veos Pharma’s European and Canadian e-commerce systems.
Upon completion, Veos will assume full operational control of the Canadian Amazon accounts, trademarks, and inventory.
Its product ecosystem includes leading natural-health and OTC brands such as ThymoTropin™, StroVia™, OleoSorb™, VEOX-Preserve™, and a growing suite of Amazon-native wellness and pet-care products.
Calle Núñez de Balboa, 35 A-5 Planta Oficina A1 28001 Madrid, Spain
Email: info@veospharma.com
Website: www.veospharma.com
Veos Pharmaceuticals Expands North American Presence with Acquisition of SSD Trading Canada’s Amazon Wellness Portfolio.
Spanish specialty healthcare company strengthens its footprint in Canada through the acquisition of leading Amazon-native consumer health and pet-care brands.
Madrid, Spain — November 14, 2025 — Veos Pharmaceuticals S.L. (“Veos” or the “Company”), a Madrid-based specialty healthcare and consumer wellness company, announced today that it has signed a definitive agreement to acquire, in an all-cash transaction, the Canadian Amazon operations and wellness brand portfolio of SSD Trading Canada 18 Ltd. The acquisition includes three established Amazon.ca brands: Copper Heal™, Petting is Caring™, and F1TNERGY™.
The transaction is expected to close within the next four weeks, subject to customary closing conditions.
Strengthening Veos Pharma’s North American Strategy
This acquisition marks an important step in Veos Pharmaceuticals’ international expansion, reinforcing the Company’s presence in North America and aligning with its strategy to scale a diversified portfolio of natural wellness and OTC consumer-health products.The acquired brands collectively generated nearly CAD $0.5 million in verified net sales during the last fiscal year and benefit from thousands of 4- and 5-star reviews from Canadian consumers. They occupy strong positions in their Amazon categories and have proven long-term demand.
“These Canadian brands have earned deep trust from consumers, and they fit perfectly within our strategy of building a global portfolio of high-quality, data-driven wellness products,” said Dr. Bassam Damaj, President and CEO of Veos Pharmaceuticals. “Our Amazon infrastructure and digital marketing capabilities will strengthen their reach and accelerate their growth.”
Integration Into Veos’ Global Consumer Health Platform
Following the closing, the SSD Trading Canada brands will be integrated into Veos’ Consumer Health Division, which manages the Company’s global direct-to-consumer (DTC) and e-commerce operations across Europe and North America.Veos will maintain the brands’ Canadian market identity, while enhancing product availability, marketing performance, inventory planning, and operational efficiency through centralized logistics and digital-commerce systems.
“These are exactly the type of high-performing assets we look for: established, profitable, and trusted by consumers,” said Samira Wifak, Managing Partner at Veos Ventures. “By integrating SSD’s portfolio into our broader consumer-health platform, we will preserve each brand’s market strength and unlock additional scale through our data-driven supply chain and marketing infrastructure.”
Expected Financial Contribution
The acquisition is expected to be immediately accretive to Veos’ 2025 financial performance.Projected first-year ROI is above 50%, driven by marketing efficiencies, improved logistics, and operational consolidation between Veos Pharma’s European and Canadian e-commerce systems.
Upon completion, Veos will assume full operational control of the Canadian Amazon accounts, trademarks, and inventory.
About Veos Pharmaceuticals
Veos Pharmaceuticals S.L. is a Madrid-based specialty healthcare and consumer-wellness company focused on developing, acquiring, and marketing scientifically validated natural health solutions and OTC medical products. Veos operates across Europe and North America through a growing portfolio of direct-to-consumer brands.Its product ecosystem includes leading natural-health and OTC brands such as ThymoTropin™, StroVia™, OleoSorb™, VEOX-Preserve™, and a growing suite of Amazon-native wellness and pet-care products.
Forward-Looking Statements
This announcement includes forward-looking statements concerning the expected timing of the transaction closing, operational integration, and anticipated financial results. These statements are based on current expectations and involve risks and uncertainties, including market dynamics, regulatory processes, and integration execution. Actual results may differ materially.Media & Investor Contact
Veos Pharmaceuticals S.L.Calle Núñez de Balboa, 35 A-5 Planta Oficina A1 28001 Madrid, Spain
Email: info@veospharma.com
Website: www.veospharma.com
